Pharmacogenomics of Drug Disposition: From Polymorphisms to BiomarkersUrs A. Meyer, Emeritus Professor, Biozentrum, University of Basel speaking at ADMET Europe 2011
Clinical Trials Utilising Radioactivity in Support of Drug DevelopmentStephen Madden, Head, Metabolism and Pharmacokinetics, Charles River speaking at ADMET Europe 2011
Use of Informatics Approaches in Risk AssessmentsSandeep Modi, Cheminformatician, Unilever speaking at ADMET Europe 2011
Drug Metabolism and Toxicity: Influence of Genetic and Epigenetic FactorsMagnus Ingelman-Sundberg, Professor and Head of Pharmacogenetics, Karolinska Institutet speaking at ADMET Europe 2011
Physiologically Based Pharmacokinetic/Pharmacodynamic Modelling for Lead Optimisation of CNS-Active TherapeuticsSimon Thomas, Cyprotex, speaking at Screening Europe 2010
Predicting Hepatotoxicity with CellCiphr HCS technology: Rat and Human Hepatotoxicity Predicton: Validation and Case StudiesKatya Tsaioun, CSO, Cyprotex speaking at ADMET Europe 2011
Metabolomics Platform for Toxicology Research in ZebrafishElwin Verheij, TNO, speaking at European Biomarkers Summit 2010.
A Novel Strategy for Bespoke Tissue-Specific Biomarkers for Drug DevelopmentGary Coulton, Director, University of London, speaking at European Biomarkers Summit 2010.
Dried Blood Spot Samples for ADME, Biomarker Analysis and MetabolomicsElwin Verheij, Innovation Manager, TNO, speaking at ADMET Europe
About Us | Advertise On This Site | Cookies | Contact Us | Home | Support | Terms & Conditions